SCN8A encephalopathy: Research progress and prospects

Epilepsia

Volumn 57, Issue 7, 2016, Pages 1027-1035

  Meisler, Miriam H ^a   Helman, Guy ^b   Hammer, Michael F ^c   Fureman, Brandy E ^d   Gaillard, William D ^b   Goldin, Alan L ^e   Hirose, Shinichi ^f   Ishii, Atsushi ^f   Kroner, Barbara L ^g   Lossin, Christoph ^h   Mefford, Heather C ⁱ   Parent, Jack M ^j   Patel, Manoj ^k   Schreiber, John ^b   Stewart, Randall ^d   Whittemore, Vicky ^d   Wilcox, Karen ^l   Wagnon, Jacy L ^a   Pearl, Phillip L ^m   Vanderver, Adeline ^b,n   Scheffer, Ingrid E ^o,p,q   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g RTI INTERNATIONAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^k UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ GEORGE WASHINGTON UNIVERSITY   (United States)

^o ROYAL CHILDREN'S HOSPITAL   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

^q FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

more..

Author keywords

Bioregistry; Drug screening; Encephalopathy; Mutation; Nav1.6; SCN8A; Sodium channel

Indexed keywords

SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.6;

ALTERNATIVE RNA SPLICING; ARTICLE; BRAIN DISEASE; BRAIN ELECTROPHYSIOLOGY; CLINICAL FEATURE; GENE MUTATION; HUMAN; INTRON; MEDICAL RESEARCH; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SEVERE MYOCLONIC EPILEPSY IN INFANCY;

EID: 84977583395     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13422     Document Type: Article

References (70)

1. Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012;129:256–264.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51:676–685.
3. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol 2015;6:104.
4. Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013;45:825–830.
5. Olson HE, Tambunan D, LaCoursiere C, et al. Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome. Am J Med Genet A 2015;167A:2017–2025.
6. Heron SE, Crossland KM, Andermann E, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 2002;360:851–852.
7. Brunklaus A, Zuberi SM. Dravet syndrome–from epileptic encephalopathy to channelopathy. Epilepsia 2014;55:979–984.
8. Berkovic SF, Heron SE, Giordano L, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 2004;55:550–557.
9. Holland KD, Kearney JA, Glauser TA, et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett 2008;433:65–70.
10. Haug K, Hallmann K, Rebstock J, et al. The voltage-gated sodium channel gene SCN2A and idiopathic generalized epilepsy. Epilepsy Res 2001;47:243–246.
11. Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68:1327–1332.
12. de Kovel CG, Meisler MH, Brilstra EH, et al. Characterization of a de novo SCN8A mutation in a patient with epileptic encephalopathy. Epilepsy Res 2014;108:1511–1518.
13. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015;84:480–489.
14. Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. Hum Mol Genet 2015;24:506–515.
15. Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000;24:343–345.
16. Veeramah KR, O'Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012;90:502–510.
17. Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephalopathies. Nature 2013;501:217–221.
18. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 2015;56:707–716.
19. Blanchard MG, Willemsen MH, Walker JB, et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet 2015;52:330–337.
20. Boerma RS, Braun KP, van de Broek MP, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 2016;13:192–197.
21. Dyment DA, Tétreault M, Beaulieu CL, et al. Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study. Clin Genet 2015;88:34–40.
22. Estacion M, O'Brien JE, Conravey A, et al. A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy. Neurobiol Dis 2014;69:117–123.
23. Kong W, Zhang Y, Gao Y, et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia 2015;56:431–438.
24. Ohba C, Kato M, Takahashi S, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia 2014;55:994–1000.
25. Singh R, Jayapal S, Goyal S, et al. Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation. Seizure 2015;26:69–71.
26. Vaher U, Noukas M, Nikopensius T, et al. De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders. J Child Neurol 2014;29:NP202-206.
27. Fung LW, Kwok SL, Tsui KW. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia 2015;56:1319–1320.
28. Takahashi S, Yamamoto S, Okayama A, et al. Electroclinical features of epileptic encephalopathy caused by SCN8A mutation. Pediatr Int 2015;57:758–762.
29. O'Brien JE, Meisler MH. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. Front Genet 2013;4:213.
30. Hammer M, Wagnon J, Mefford H, et al. SCN8A epileptic encephalopathy. Gene Rev 2016; In press.
31. Howell KB, McMahon JM, Carvill GL, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology 2015;85:958–966.
32. Calhoun JD, Isom LL. The role of non-pore-forming beta subunits in physiology and pathophysiology of voltage-gated sodium channels. Handb Exp Pharmacol 2014;221:51–89.
33. Silva J. Slow inactivation of Na(+) channels. Handb Exp Pharmacol 2014;221:33–49.
34. Noujaim SF, Kaur K, Milstein M, et al. A null mutation of the neuronal sodium channel NaV1.6 disrupts action potential propagation and excitation-contraction coupling in the mouse heart. FASEB J 2012;26:63–72.
35. Poulet C, Wettwer E, Grunnet M, et al. Late sodium current in human atrial cardiomyocytes from patients in sinus rhythm and atrial fibrillation. PLoS ONE 2015;10:e0131432.
36. Mishra S, Reznikov V, Maltsev VA, et al. Contribution of sodium channel neuronal isoform Nav1.1 to late sodium current in ventricular myocytes from failing hearts. J Physiol 2015;593:1409–1427.
37. Smith MR, Smith RD, Plummer NW, et al. Functional analysis of the mouse Scn8a sodium channel. J Neurosci 1998;18:6093–6102.
38. Plummer NW, McBurney MW, Meisler MH. Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells. J Biol Chem 1997;272:24008–24015.
39. O'Brien JE, Drews VL, Jones JM, et al. Rbfox proteins regulate alternative splicing of neuronal sodium channel SCN8A. Mol Cell Neurosci 2012;49:120–126.
40. Caldwell JH, Schaller KL, Lasher RS, et al. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc Natl Acad Sci USA 2000;97:5616–5620.
41. Boiko T, Rasband MN, Levinson SR, et al. Compact myelin dictates the differential targeting of two sodium channel isoforms in the same axon. Neuron 2001;30:91–104.
42. Boiko T, Van Wart A, Caldwell JH, et al. Functional specialization of the axon initial segment by isoform-specific sodium channel targeting. J Neurosci 2003;23:2306–2313.
43. Gasser A, Ho TS, Cheng X, et al. An ankyrinG-binding motif is necessary and sufficient for targeting Nav1.6 sodium channels to axon initial segments and nodes of Ranvier. J Neurosci 2012;32:7232–7243.
44. Van Wart A, Trimmer JS, Matthews G. Polarized distribution of ion channels within microdomains of the axon initial segment. J Comp Neurol 2007;500:339–352.
45. Osorio N, Cathala L, Meisler MH, et al. Persistent Nav1.6 current at axon initial segments tunes spike timing of cerebellar granule cells. J Physiol 2010;588:651–670.
46. Osorio N, Alcaraz G, Padilla F, et al. Differential targeting and functional specialization of sodium channels in cultured cerebellar granule cells. J Physiol 2005;569:801–816.
47. Cruz JS, Silva DF, Ribeiro LA, et al. Resurgent Na+ current: a new avenue to neuronal excitability control. Life Sci 2011;89:564–569.
48. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005;115:2010–2017.
49. Makinson CD, Tanaka BS, Lamar T, et al. Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance. Neurobiol Dis 2014;68:16–25.
50. Kohrman DC, Harris JB, Meisler MH. Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT-AC intron. J Biol Chem 1996;271:17576–17581.
51. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–249.
52. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812–3814.
53. Zweig AS, Karolchik D, Kuhn RM, et al. UCSC genome browser tutorial. Genomics 2008;92:75–84.
54. Wagnon JL, Barker BS, Hounshell JA, et al. Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy. Ann Clin Transl Neurol 2016;3:114–123.
55. Chahine M, George AL Jr, Zhou M, et al. Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation. Neuron 1994;12:281–294.
56. Moller RS, Heron SE, Larsen LH, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia 2015;56:e114–e120.
57. Trudeau MM, Dalton JC, Day JW, et al. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet 2006;43:527–530.
58. Gardella E, Becker F, Moller RS, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol 2016;79:428–436.
59. Liu Y, Lopez-Santiago LF, Yuan Y, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol 2013;74:128–139.
60. Higurashi N, Uchida T, Lossin C, et al. A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain 2013;6:19.
61. Jiao J, Yang Y, Shi Y, et al. Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons. Hum Mol Genet 2013;22:4241–4252.
62. Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013;4:2410.
63. Dinday MT, Baraban SC. Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of Dravet syndrome(1,2,3). eNeuro 2015;2.
64. The NIH/NINDS Anticonvulsant Screening Program (ASP): recommendations from the working group's 2012 review of the Program. Epilepsia 2012;53:1837–1839.
65. Jones JM, Meisler MH. Modeling human epilepsy by TALEN targeting of mouse sodium channel Scn8a. Genesis 2014;52:141–148.
66. Gattone P, Lammert W. The epilepsy foundation leads in the rare epilepsy network PCORI award. Epilepsy Behav 2014;39:65.
67. McTague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 2016;15:304–316.
68. Lotte J, Bast T, Borusiak P, et al. Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Seizure 2016;35:106–110.
69. Berg AT, Jallon P, Preux PM. The epidemiology of seizure disorders in infancy and childhood: definitions and classifications. Handb Clin Neurol 2013;111:391–398.
70. Berg AT, Millichap JJ. The 2010 revised classification of seizures and epilepsy. Continuum (Minneap Minn) 2013;19:571–597.